The Automation Partnership (TAP) has announced that David Phillips has joined the board of the Company as Commercial Director.
The Automation Partnership (TAP) has announced that David Phillips has joined the board of the Company as Commercial Director.
In this critical leadership role, Mr Phillips will have executive responsibility for the global sales, marketing and business development activities of TAP's drug discovery, genomics and cell culture divisions.
TAP Chief Executive Richard Archer, commented, "I am delighted that David has joined TAP.
"He has exceptional experience both in our current areas of activity and in the new areas of business we are pursuing.
"David's arrival continues the process of broadening and developing the executive management team at TAP and he is a key part of our future plans for the business." "I am thrilled to be joining The Automation Partnership team," stated Mr Phillips.
"I look forward to building upon the world-class brand name and market reputation TAP has already established and developing new opportunities that will promote continued growth.
"I am excited to utilise my business development experience, as well as my background in both Obig pharmaceuticalû and start-up environments, to help shape TAP's long term strategy and forge significant partnerships, alliances and joint ventures," he added.
Mr Phillips brings to TAP a wealth of experience in both the pharmaceutical and biotechnology industries.
Most recently, he served as Chief Commercial Officer with Argenta Discovery, where he delivered commercial leadership worldwide and established key strategic partnerships with companies such as GlaxoSmithKline.
Previously, Mr Phillips was Chief Executive Officer of Oxxon Pharmaccines, where he was instrumental in establishing that early stage company as a competitive force in the therapeutic vaccine sector. Responsible for overall management of the company, Mr Phillips successfully created and achieved the business plan, forged relationships with key influential audiences and secured second round funding.
Mr Phillips was instrumental in the establishment of Cambridge Discovery Chemistry.
On its acquisition by Oxford Molecular, he held several positions including Vice President, Business Development and Vice President, Group Sales and Marketing.
He was employed by GlaxoWellcome plc for fourteen years, where he held key marketing and sales roles including Head of Cardiovascular, Diabetes and New Therapy Areas Group.
